Heron Therapeutics Inc

HRTX remains in a Stage 4 decline with a clear sequence of lower highs and lower lows. Price trades below the 9, 21, and 50 EMAs, which continue to slope down and act as resistance. Although a Post-Capitulation pattern indicates selling exhaustion at the recent low, the absence of any repair above intermediate EMAs confirms medium-term bearish control. The tradable side is bearish, and execution should involve selling now into failed retests of the short-term EMAs. Key risks include a decisive reclaim of the 9/21 EMAs and a sustained break above the 50 SMA that could invalidate the downtrend.

• ↑APONVIE sales grew 74% YoY, driving surgical NK-1 segment momentum
• ↑Tax Benefit Preservation Plan extended to July 2029 enhances cash runway
• ↓Q2 net loss of $5.5M and $0.03 EPS missed consensus